Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Unpaywall

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

European Journal of CancerNov 1, 2016

Loading next page...
 
/lp/unpaywall/health-related-quality-of-life-in-the-randomised-keynote-002-study-of-k75ovlKgd2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Unpaywall
ISSN
0959-8049
DOI
10.1016/j.ejca.2016.07.018
Publisher site
See Article on Publisher Site

Abstract

Journal

European Journal of CancerUnpaywall

Published: Nov 1, 2016

There are no references for this article.